Who are Keflex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fetroja, Zerbaxa, Teflaro, Cefditoren Pivoxyl, Omnicef, Maxipime.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cefalexin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Keflex — Competitive Intelligence Brief

Keflex (cefalexin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cephalosporin Antibacterial. Area: Metabolic.

marketed Cephalosporin Antibacterial Solute carrier family 15 member 2 Metabolic Live · refreshed every 30 min

Target snapshot

Keflex (cefalexin) — Shionogi.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Keflex TARGET	cefalexin	Shionogi	marketed	Cephalosporin Antibacterial	Solute carrier family 15 member 2	1971-01-01
Fetroja	CEFIDEROCOL	Shionogi	marketed	Cephalosporin Antibacterial		2019-01-01
Zerbaxa	CEFTOLOZANE	Cubist Pharms	marketed	Cephalosporin Antibacterial		2014-01-01
Teflaro	CEFTAROLINE FOSAMIL	AbbVie	marketed	Cephalosporin Antibacterial		2010-01-01
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	marketed	Cephalosporin Antibacterial		2001-01-01
Omnicef	CEFDINIR		marketed	Cephalosporin Antibacterial [EPC]		1997-01-01
Maxipime	CEFEPIME	Baxter	marketed	Cephalosporin Antibacterial		1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-05-15 — Zerbaxa · 7129232 · US
2032-09-07 — Zerbaxa · 10028963 · US
2032-09-07 — Zerbaxa · 9724353 · US
2032-09-27 — Zerbaxa · 8476425 · US
2032-09-27 — Zerbaxa · 8685957 · US
2034-03-14 — Zerbaxa · 10420841 · US
2034-03-14 — Zerbaxa · 11278622 · US
2034-03-14 — Zerbaxa · 8968753 · US
2034-03-14 — Zerbaxa · 9320740 · US
2034-03-14 — Zerbaxa · 9872906 · US
2034-05-28 — Zerbaxa · 8906898 · US
2034-09-09 — Zerbaxa · 10376496 · US
2034-09-09 — Zerbaxa · 10933053 · US
2035-08-14 — Zerbaxa · 10125149 · US

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Keflex — Competitive Intelligence Brief. https://druglandscape.com/ci/cefalexin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab